Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 1:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 5,050 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Capsule 2 Clear all
Completed No phase listed Observational

Marijuana Drug Discrimination and Self-Administration

NCT00943930
View directory record Official record
Conditions
Marijuana Abuse
Interventions
THC (delta-9 tetrahydrocannabinol), d-amphetamine, oral THC
Drug
Lead sponsor
Wayne State University
Other
Eligibility
21 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 29, 2026, 1:12 AM EDT
Completed Not applicable Interventional

Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir

NCT02113631
View directory record Official record
Conditions
Hepatitis C, Chronic, Cirrhosis
Interventions
Telaprevir, Boceprevir, Peg-IFN, Ribavirin
Drug
Lead sponsor
Louis Stokes VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 29, 2026, 1:12 AM EDT
Completed Phase 2 Interventional

TC-5214 as add-on the Treatment of Major Depressive Disorder

NCT00692445
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
TC-5214 + citalopram, Placebo + citalopram
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Miami, Florida • Cincinnati, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 29, 2026, 1:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults

NCT05040295
View directory record Official record
Conditions
Healthy Participants
Interventions
ritlecitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 29, 2026, 1:12 AM EDT
Completed Phase 2 Interventional Results available

This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines

NCT03926611
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 Arm 1, LOU064 Arm 2, LOU064 Arm 3, LOU064 Arm 4, LOU064 Arm 5, LOU064 Arm 6, Placebo arm
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
11
States / cities
Litchfield Park, Arizona • Little Rock, Arkansas • Mission Viejo, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 29, 2026, 1:12 AM EDT
Recruiting Phase 2 Interventional

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

NCT07271667
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, B-cell Malignancies
Interventions
Emavusertib, Zanubrutinib
Drug
Lead sponsor
Curis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
6
States / cities
Miami Beach, Florida • Rochester, Minnesota • Florham Park, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 29, 2026, 1:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Eicosapentaenoic Acid and Protein Modulation to Induce Anabolism in Chronic Obstructive Pulmonary Disease (COPD): Aim 2

NCT01624792
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Muscle Wasting
Interventions
Olive oil, Fish oil, Fish oil and placebo
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 29, 2026, 1:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Antibiotics on Enteric Neurons and Glia

NCT05834036
View directory record Official record
Conditions
Antibiotic Enterocolitis
Interventions
Amoxicillin Oral Capsule
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 29, 2026, 1:12 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

NCT05511363
View directory record Official record
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
KarXT, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
55 Years to 90 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
59
States / cities
Homewood, Alabama • Phoenix, Arizona • Encino, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 29, 2026, 1:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Health1: A Study of Health and Wellness Formulations and Their Effects on Overall Health

NCT05783232
View directory record Official record
Conditions
Sleep, Pain, Depression, Anxiety
Interventions
Placebo Control Form 1 Capsules, Health Active Study Product 1.1 Capsules, Health Active Study Product 1.2 Capsules, Health Active Study Product 1.3 Capsules
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
1,494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 29, 2026, 1:12 AM EDT
Completed Phase 2 Interventional Results available

Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients

NCT04523181
View directory record Official record
Conditions
Covid-19
Interventions
Antroquinonol, Placebo
Drug · Other
Lead sponsor
Golden Biotechnology Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Michigan City, Indiana • Wichita, Kansas • Rockville, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 29, 2026, 1:12 AM EDT
Completed Phase 3 Interventional

A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Mild to Moderate Pneumonia in Adult Patients

NCT00643734
View directory record Official record
Conditions
Pneumonia
Interventions
azithromycin sustained release, placebo, levofloxacin
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
35
States / cities
Mesa, Arizona • Phoenix, Arizona • San Luis Obispo, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2008 · Synced Oct 29, 2026, 1:12 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

NCT01150357
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren (6.25/12.5/25 mg), Aliskiren (37.5/75/150 mg), Aliskiren (150/300/600 mg)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Oct 29, 2026, 1:12 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088

NCT06579300
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-1088, Placebo for ABBV-1088, Itraconazole (ITZ)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 29, 2026, 1:12 AM EDT
Completed Phase 2 Interventional

Effect of Cinnamon on Glucose and Lipid Levels in Non-Insulin Dependent Type 2 Diabetes Mellitus

NCT00237640
View directory record Official record
Conditions
Diabetes Mellitus, Adult Onset
Interventions
Cinnamon or placebo 500 mg capsule twice daily
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 22, 2008 · Synced Oct 29, 2026, 1:12 AM EDT
Completed Phase 2 Interventional Results available

Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids

NCT01090024
View directory record Official record
Conditions
Asthma
Interventions
BI 671800, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Huntington Beach, California • Mission Viejo, California • Stockton, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 29, 2026, 1:12 AM EDT
Completed Phase 4 Interventional Results available

CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat

NCT02579096
View directory record Official record
Conditions
Gout, Chronic Kidney Diseases
Interventions
allopurinol capsule, 100-800 mg by mouth once daily, febuxostat tablet 40-120 mg by mouth once daily, Placebo, vehicle control (febuxostat-shaped), Placebo, vehicle control (allopurinol-shaped)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
23
States / cities
Loma Linda, California • San Diego, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 29, 2026, 1:12 AM EDT
Recruiting Phase 4 Interventional

Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

NCT01225913
View directory record Official record
Conditions
Asthma
Interventions
fluticasone/salmeterol in all asthmatics, budesonide/formoterol or fluticasone/salmeterol in all asthmatics
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
10 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 29, 2026, 1:12 AM EDT
Recruiting Phase 4 Interventional

Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder

NCT06269627
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Acamprosate calcium, Placebo
Drug · Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 29, 2026, 1:12 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

NCT01239797
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma
Interventions
Lenalidomide, Dexamethasone, Dexamethasone (Oral), Dexamethasone (IV), Elotuzumab (BMS-901608; HuLuc63)
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
63
States / cities
Muscle Shoals, Alabama • Tucson, Arizona • Berkeley, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 29, 2026, 1:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

NCT06440980
View directory record Official record
Conditions
Healthy, Obese, Overweight, Obesity
Interventions
Orforglipron
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
533 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
7
States / cities
Anaheim, California • Los Alamitos, California • Daytona Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 29, 2026, 1:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function

NCT01761773
View directory record Official record
Conditions
Healthy, Renal Impairment
Interventions
cabozantinib
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 29, 2026, 1:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

MPC-004 for the Treatment of an Acute Gout Flare

NCT00506883
View directory record Official record
Conditions
Gout
Interventions
High Dose Colchicine (4.8 mg total dose), Low Dose Colchicine (1.8mg total dose), Placebo Control
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
83
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 29, 2026, 1:12 AM EDT
Completed Not applicable Interventional

Effects of Epicatechin on Functional Capacity, Skeletal Muscle Structure and Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction (HFPEF)

NCT02068040
View directory record Official record
Conditions
Heart Failure
Interventions
CocoaVia
Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 29, 2026, 1:12 AM EDT